{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:05:28Z","timestamp":1787501128076,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","award":["0.21\u20130.40"],"award-info":[{"award-number":["0.21\u20130.40"]}],"id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["Salud-2012\u201301\u2013181,031"],"award-info":[{"award-number":["Salud-2012\u201301\u2013181,031"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.msard.2021.103266","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T02:34:22Z","timestamp":1631673262000},"page":"103266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab"],"prefix":"10.1016","volume":"56","author":[{"given":"J.","family":"Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Anguiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rivas\u2013Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gonz\u00e1lez-Conchillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rez-Saldivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maga\u00f1a-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mart\u00ednez-Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ordo\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103266_bib0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1099\/0022-1317-82-5-1221","article-title":"Genotypes of JC virus in East, Central and Southwest Europe","volume":"82","author":"Agostini","year":"2001","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.msard.2021.103266_bib0002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103266_bib0003","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-3083.1991.tb01594.x","article-title":"Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality","volume":"34","author":"Boyum","year":"1991","journal-title":"Scand J Immunol"},{"issue":"6","key":"10.1016\/j.msard.2021.103266_bib0004","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.24148","article-title":"JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis","volume":"75","author":"Chalkias","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103266_bib0005","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in multiple sclerosis: long-term management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2021.103266_bib0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13550280152537201","article-title":"Predicted amino acid sequences for 100 JCV strains","volume":"7","author":"Cubitt","year":"2001","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2021.103266_bib0007","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ene.12834","article-title":"Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients","volume":"23","author":"Dominguez-Mozo","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103266_bib0008","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.msard.2021.103266_bib0009","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2021.103266_bib0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.103266_bib0011","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1099\/0022-1317-79-10-2491","article-title":"Phylogenetic analysis of 22 complete genomes of the human polyomavirus JC virus","volume":"79","author":"Jobes","year":"1998","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.msard.2021.103266_bib0012","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11481-012-9366-z","article-title":"Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification","volume":"7","author":"Laroni","year":"2012","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.msard.2021.103266_bib0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.virol.2008.12.021","article-title":"The Polyomaviridae: contributions of virus structure to our understanding of virus receptors and infectious entry","volume":"384","author":"Neu","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.msard.2021.103266_bib0014","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s13365-015-0338-y","article-title":"Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment","volume":"21","author":"Pietropaolo","year":"2015","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2021.103266_bib0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103266_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2020.102008","article-title":"Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?","volume":"41","author":"Prezioso","year":"2020","journal-title":"Mult Scler. Relat Disor."},{"key":"10.1016\/j.msard.2021.103266_bib0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J."},{"issue":"2","key":"10.1016\/j.msard.2021.103266_bib0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysisi of JG Virus DNA from Natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J. Infect, Dis."},{"key":"10.1016\/j.msard.2021.103266_bib0019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mcp.2014.11.007","article-title":"Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients","volume":"29","author":"Rossi","year":"2015","journal-title":"Mol. Cell. Probes."},{"key":"10.1016\/j.msard.2021.103266_bib0020","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1352458515607651","article-title":"PML risk stratification using anti-JCV antibody index and l-selectin","volume":"22","author":"Schwab","year":"2016","journal-title":"Mult Scler"},{"issue":"17","key":"10.1016\/j.msard.2021.103266_bib0021","doi-asserted-by":"crossref","first-page":"9191","DOI":"10.1073\/pnas.94.17.9191","article-title":"Typing of urinary JC virus DNA offers a novel means of tracing human migrations","volume":"94","author":"Sugimoto","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"issue":"22","key":"10.1016\/j.msard.2021.103266_bib0022","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103266_bib0023","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40263-014-0168-0","article-title":"Natalizumab: risk stratification of individual patients with multiple sclerosis","volume":"28","author":"Tur","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103266_bib0024","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1099\/vir.0.80863-0","article-title":"New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy","volume":"86","author":"Zheng","year":"2005","journal-title":"J Gen Virol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:00Z","timestamp":1761901380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821005332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":24,"alternative-id":["S2211034821005332"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103266","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103266"}}